Infographic: Pneumococcal Vaccination Quality Improvement Outcomes

To support broad initiatives to improve the health of the public through the education of healthcare providers and patients, the Alliance and Pfizer partnered to create project opportunities focused on increasing immunization rates of adults aged 19–64 years with immunocompromising conditions who are at increased risk for pneumococcal disease.